Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals reported Q3 and YTD 2026 results, with revenue up 14% and 19% respectively. Net product sales of LUPKYNIS increased 12% and 18%. Net income rose 21% and 67%. The company raised its 2026 revenue guidance and initiated new clinical studies for LUPKYNIS and aritinercept.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest near‑term upside, but future trial data remain a key catalyst.
Market read
Strong earnings and raised guidance could drive AUPH higher, with spill‑over to similar biotech stocks.
What to watch
Potential risks from upcoming Phase 4 PRESERVE trial outcomes could temper enthusiasm.
Background
Aurinia's LUPKYNIS is the first FDA‑approved oral therapy for lupus nephritis; the company is expanding its pipeline with the PRESERVE study and a new BAFF/APRIL inhibitor.
Ticker impact
Aurinia Pharmaceuticals released its Q3 and nine‑month 2026 financial results and raised its 2026 revenue guidance.
likely upward pressure as market prices in higher revenue outlook
Revenue and net product sales grew double‑digit year‑over‑year and guidance was increased, which typically supports a price rally.
Market effects
Positive earnings may lift the broader autoimmune‑therapy biotech sector.
Urinia is US‑listed; impact confined to US biotech equities.
Limited to investors tracking niche biotech earnings.
Counterpoint
If guidance is still modest relative to peers, the rally could be muted.
Key entities
- companyAurinia Pharmaceuticals Inc.
Biopharma focused on autoimmune diseases, ticker AUPH.
- productLUPKYNIS
Oral therapy for lupus nephritis.
